Synthesis of potent and highly selective nonguanidine azetidinone inhibitors of human tryptase

  • Bioorg Med Chem Lett. 2004 May 3;14(9):2227-31. doi: 10.1016/j.bmcl.2004.02.011.
Gregory S Bisacchi  1 ,  William A Slusarchyk ,  Scott A Bolton ,  Karen S Hartl ,  Glenn Jacobs ,  Arvind Mathur ,  Wei Meng ,  Martin L Ogletree ,  Zulan Pi ,  James C Sutton ,  Uwe Treuner ,  Robert Zahler ,  Guohua Zhao ,  Steven M Seiler
Affiliations
  • 1. The Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 5400, Princeton, NJ 08543-5400, USA. [email protected]
PMID: 15081014 DOI: 10.1016/j.bmcl.2004.02.011
Abstract

Azetidinones such as BMS-363131 (2) and BMS-363130 (3), which contain a guanidine group in the C-3 side chain were previously shown to be very potent inhibitors of human tryptase with high selectivity versus other serine proteases, including trypsin. In this letter, we describe the discovery of a number of potent azetidinone tryptase inhibitors in which the guanidine moiety at the ring C-3 position is replaced with primary or secondary amine or aminopyridine functionality. In particular, BMS-354326 (4) is a highly potent tryptase inhibitor (IC(50)=1.8 nM), which has excellent selectivity against trypsin and most other related serine proteases.

Products